Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model.
about
The glutamatergic system as a target for neuropathic pain reliefInteractions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterizationBioisosterism of urea-based GCPII inhibitors: Synthesis and structure–activity relationship studiesMice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injuryMR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused UltrasoundNAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammationNAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide familyPhencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats.Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonistsSelective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration.Therapeutic potential of metabotropic glutamate receptor modulators.Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophreniaNAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disordersCurrent approaches with the glutamatergic system as targets in the treatment of neuropathic pain.Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation.Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancerBlockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseN-acetylaspartylglutamate is an agonist at mGluR₃ in vivo and in vitro.Nociception modulation by supraspinal group III metabotropic glutamate receptors.A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA.NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury.NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia.Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model.NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxiaIntracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain.Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBINAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat.Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system.Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs.Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation
P2860
Q27006077-41B3D6BE-C285-4A81-89E8-AFB4D265788BQ27653047-4665D65A-6C54-4359-8CDC-3308C0C52400Q27658096-C7DE1F30-B7FD-433F-9C0B-999B2ED7FBB2Q28274467-EB472598-BAAD-4A01-B84D-B1575E06BF8CQ28817563-8EF74FCE-9600-426B-9395-A7760DE15001Q30459203-5E1A2920-F275-4D2B-B3B1-327018663D6EQ30465008-4F92DCDD-3974-4950-8E48-78B6E057255DQ30465259-ECC52B8B-3287-4780-B228-A203F067B72FQ30491856-23FF56B6-F8DE-45F4-A3DA-B388DA98A7A8Q34256889-B8AB3E39-86AF-4DEA-B434-A2F65B1E6FB5Q34293335-2D537AF9-111D-409F-BAA3-7C0574A6EFD5Q34537679-F32DE3D9-3AB4-4B9D-B0DA-8D23CB77D351Q35685315-C4B73EAD-C8C7-4AA1-A5C3-322293CEFE2DQ35778704-7F75BE6C-0293-4BF9-8C87-165918962164Q36052391-95FFAAA1-B5F1-43AC-ACEA-ADAE0B588CF6Q36675499-8B8CB38E-AB0D-4275-B18C-E8729C9F2057Q36868552-2ED1ABBA-C4F4-49EA-B1AD-2BDB20281D68Q37523991-92DFF45A-B7DD-4211-A58C-12F3C43C25BEQ37605348-8A25643E-6B47-4BE7-831E-7D8B6E0B0A3CQ37861794-DA3B79BB-1AC1-47A9-AB7D-A6C438183E3AQ37972920-C88A047D-4E90-4056-BABB-560FD90C52A6Q38185090-B4094B59-5FF8-4F2F-873C-8296F536F780Q38831232-55C6ED95-D1FF-4217-9905-F56E3C2B2B60Q38833017-9C5C8F3B-8C3B-4B5E-AE0B-AFD2E05B4002Q38882060-F565E374-0BF2-4894-8389-3656E46F0C76Q38887993-B10F3F4A-5774-4B26-9B71-C89F03CAB89BQ38912835-911DFEEA-DD1E-4BA5-84BB-6AE7BAD0C00DQ40475257-E5D53FFC-2128-446A-9097-C0F4391D2D6CQ41074666-4A66539C-E903-4FE2-BE2D-58508DDD1226Q41512816-A4CBA9D8-0CEB-4F92-AE13-FF369984EC92Q42065018-77264310-4664-47E6-AA9C-EF40ADAABF63Q42285300-769832B4-119E-40D3-AF7D-A781F72CB0C6Q42397202-C611D110-0C3A-4EDC-A1F2-37DFA3F1E964Q42742435-2192723A-0116-4D81-8FCF-F376EC46A4AFQ46142561-91F450B9-17D8-43C4-BD5A-E3BAA7C8ECB3Q46242349-E6AD1A84-BD67-44C3-92CD-F3A7E3AD4014Q48171011-9D617834-7403-4541-B6B7-46F669DD0D0CQ57816814-2093EDDF-96E7-4846-921F-FB7536F32CED
P2860
Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antinociceptive effects of N-a ...... he rat neuropathic pain model.
@en
type
label
Antinociceptive effects of N-a ...... he rat neuropathic pain model.
@en
prefLabel
Antinociceptive effects of N-a ...... he rat neuropathic pain model.
@en
P2093
P2860
P1476
Antinociceptive effects of N-a ...... he rat neuropathic pain model.
@en
P2093
Alan Kozikowski
Barbara Wroblewska
Ewa Grajkowska
Jarda Wroblewski
Joseph H Neale
Serabi Hirasawa
Tatsuo Yamamoto
P2860
P304
P356
10.1111/J.1460-9568.2004.03504.X
P407
P577
2004-07-01T00:00:00Z